Recently Acutus Medical And Biotronik Collaborated For Global Cardiac Rhythm Management Devices Batteries Market

 

Growing adoption and rapid advancement in lithium anode batteries are fostering the growth of the global cardiac rhythm management devices batteries market. The advent of lithium anode that are weight, high reliability and predictability, small size,  high energy density, and the long service life is again driving the growth of the cardiac rhythm management devices batteries market. Various institutes are focussing on R&D activities for lithium anode batteries. For instance, in July 2018, a study, ‘Ionic Liquid-Based Electrolyte Membranes for Medium-High Temperature Lithium Polymer Batteries’ published in the journal MDPI Membranes, reported the development of PEO-LiTFSI Li+-conducting membranes, containing the PYR14TFSI ionic liquid, as electrolyte separators for all-solid-state lithium polymer batteries operating at medium-high temperatures.

On the other hand, growing product recall and warnings are projected to restrict the growth of the market. For instance, in May 2019, The U.S. Food and Drug Administration (FDA) raised alarm about premature battery depletion in Azure, Astra, Percepta, Serena, and Solara pacemaker models of Medtronic, Inc.

North America is expected to hold the dominant position in the global cardiac rhythm management devices batteries market and this is attributed to the continuous launch of the innovative product by key players in the region. For instance, in Feburary 2020, Abbott announced it has received CE Mark for the new Gallant™ implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure.

Also, the region is accounted for the high prevalence of the cardiovascular disease. According to American Heart Association’s Heart Disease and Stroke Statistics 2018 At-a-Glance, CVDs accounted for nearly 836,546 deaths in the U.S. Moreover, around 2,300 deaths are registered in the U.S. due to CVDs each day, an average of 1 death every 38 seconds.

The cardiac monitor industry is witnessing exciting advances especially in the areas of cardiac monitoring, electrocardiography, and implantation of microchips into the body. The key developments such as the adoption of microchips for implantation and ultra-high-performance technologies continue to lead the way and new devices are being introduced regularly.

Key Developments:

In June 2020, Acutus Medical and Biotronik announced that they had entered a partnership to collaborate on certain electrophysiology-related products. Biotronik is engaged in the development of a suite of devices for cardiac rhythm management (CRM) that largely focuses on implantable devices.